Sugi Predict

Sugi Predict / Compounds / SCHEMBL14908640

SCHEMBL14908640

SCHEMBL14908640

Nc1cncc(-n2ccnc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.58
▸ MAPT P10636 1/20 0.58
▸ CYP3A4 P08684 2/20 0.52
▸ CYP2A6 P11509 1/20 0.52
▸ CYP11B1 P15538 3/20 0.46
▸ CYP11B2 P19099 3/20 0.46
▸ CYP19A1 P11511 2/20 0.45
▸ ENPP2 Q13822 1/20 0.44
▸ MKNK1 Q9BUB5 1/20 0.44
▸ MKNK2 Q9HBH9 1/20 0.44
▸ NOTUM Q6P988 1/20 0.44
▸ IDO1 P14902 2/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CRBN Q96SW2 1/20 0.40
▸ PDE2A O00408 1/20 0.39
▸ PDE3B Q13370 1/20 0.39
▸ PDE3A Q14432 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30463031 0.86 CYP3A4 (0.61) LMNAMAPTCYP3A4CYP2A6CYP11B1
SCHEMBL30201408 0.78 MAPT (0.52) LMNAMAPTCYP3A4CYP2A6MEN1
SCHEMBL3931376 0.78 MAPT (0.52) LMNAMAPTCYP3A4CYP2A6MEN1
SCHEMBL1559218 0.77 CYP3A4 (0.52) LMNAMAPTCYP3A4CYP2A6CYP11B1
SCHEMBL632660 0.76 IDO1 (0.64) LMNAMAPTCYP3A4CYP2A6CYP11B1
SCHEMBL30880680 0.74 LMNA (0.55) LMNAMAPTCYP3A4CYP2A6CYP11B1
SCHEMBL9609628 0.74 LMNA (0.55) LMNAMAPTCYP3A4CYP2A6CYP11B1
SCHEMBL16673120 0.74 CYP3A4 (0.62) LMNAMAPTCYP3A4CYP2A6CYP11B1
SCHEMBL159406 0.74 LMNA (1.00) LMNAMAPTCYP3A4CYP2A6CYP11B1
SCHEMBL23072043 0.73 CYP3A4 (0.47) LMNAMAPTCYP3A4CYP2A6CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 — — EP disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 — — US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-8772320-B2 — — 2014-07-08 — — US disclosed
US-8772320-B2 — — 2014-07-08 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 — — EP disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 — — EP disclosed
CN-102958918-A Novel nicotinamide derivatives or salts thereof FUJIFILM CORP 2013-03-06 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK LMNA 3649/4885MAPT 4186/4885CYP3A4 4411/4885
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK LMNA 3015/4885MAPT 470/4885CYP3A4 4198/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK LMNA 3243/4885MAPT 501/4885CYP3A4 3280/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK LMNA 3015/4885MAPT 470/4885CYP3A4 4198/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK LMNA 3115/4885MAPT 438/4885CYP3A4 4148/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK LMNA 3115/4885MAPT 438/4885CYP3A4 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.